Early Growth Hormone (GH) Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program
Authors' conclusion
GH-treated participants with TS responded well, without new safety concerns. Our real-world data are in agreement with previous studies.
Study context
- Population
- Girls with Turner syndrome (TS) treated with Norditropin; 84% prepubertal at start (effectiveness analysis set (EAS)); mean (SD) age 8.8 (3.9) years1,513 in treatment-naive EAS
- Participants
- 2,377 participants
Methodological detailsNordiNet® IOS and ANSWER program, real-world data, up to 10 years of follow-up
- NordiNet® IOS and ANSWER program
- Real-world data
- Up to 10 years of follow-up
Primary result
As reported in the abstract
Near-adult height SDS
| Group | Value | Change from baseline |
|---|---|---|
| Norditropin | mean −1.99 (SD 0.94) | +0.90 [0.85] |
Norditropin
Valuemean −1.99 (SD 0.94)
Change from baseline+0.90 [0.85]
- Reached near-adult HSDS
- 264 (17%)
Further findings
Entry into puberty (EAS) · during the study
- Participants entering puberty
- 695 (46%)
- Mean (SD) age at puberty entry
- 12.7 (1.9) years
- Whether puberty was spontaneous or induced was unknown
IGF-I SD score (SDS) (safety analysis set (SAS)) · year 10
- Mean IGF-I SDS (SD) at year 10
- 0.91 (1.69)
- Change from baseline
- +1.48 (1.70)
Safety
| Outcome | Values |
|---|---|
| Serious adverse reactions | Norditropin 10 events |
- Serious adverse reactions — Epiphysiolysis
- 3
Original publication
Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program. J Clin Endocrinol Metab. Published 22 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →